Moderna and drugmaker Merck have started a late-stage study to evaluate their experimental mRNA-based cancer vaccine in combination with cancer therapy Keytruda, the companies said on Wednesday.
The companies will study the safety and efficacy of the vaccine-Keytruda combination in patients with a type of skin cancer, compared to Keytruda alone.
Global recruitment for the trial has begun, with the first patients being enrolled in Australia, the companies said in a joint release.
Shares of Moderna rose 1% in premarket trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments